Jared Acoba is an Oncology physician affiliated with Cancer Center of Hawaii. OpenAlex indexes 126 publications with 3,904 citations (h-index 20); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
321 N Kuakini St
Suite 412
Honolulu, HI 968172364
Telephone
808-531-8521Provider last certified this registry record 12 Jan 2023.
Clinical trials
- Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
Sponsor: University of Hawaii
- TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer
Sponsor: University of Hawaii
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
53 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year202510 payments
- AstraZeneca Pharmaceuticals LPProgram year20259 payments
- Eisai Inc.Program year20259 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
45.1%Kinase inhibitor21.7%Lenvima28%Imbruvica25%Imatinib Mesylate22%Cabometyx15%Stivarga11%Part D<11 patientsCytochrome P450 17A1 Inhibitor6.8%Abiraterone Acetate64%Zytiga36%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
15.5%Corticosteroid7.7%Prednisone100%Part D<11 patientsSerotonin-3 Receptor Antagonist3.9%Ondansetron Hcl100%Part D≥12 patients+ 1 more class in this area
Nervous system
15.1%Opioid Agonist5.6%Oxycodone Hcl100%Part D≥15 patientsPhenothiazine5%Prochlorperazine Maleate100%Part D≥12 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2019–2025 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Cobolimab and dostarlimab in the first-line treatment of unresectable hepatoma: A multi-center, single arm, phase 2 trial.
Journal of Clinical Oncology
2025 - Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors
New England Journal of Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”